


# The most comprehensive single-cell omics dataset in immuno-oncology

# Why ScaiPod: biomarker-driven drug development



## ScaiPod: Precision Medicine for Immuno-Oncology



#### **Ioin ScaiPod**



We are looking for strategic partners to join and contribute to the consortium. Together we will provide a reference to standard of care in immuno-oncology, enable the most optimal positioning of new IO therapies and maximize the chances of success for new drugs in IO.

Partners:









Scailyte Inc. Basel www.scailyte.com contact@scailyte.com





# The most comprehensive single-cell omics dataset in immuno-oncology

# **Precision medicine in immunotherapy**



SCQIVISION\*
Proprietary
advanced
data analytics




(in compliance with GCLP, GDPR, and ISO standards)

data



Automation and standardization of sample processing and data generation (spatial and single-cell omics)

#### ScaiPod Module 1 - Melanoma Foundational Study\*



\*In collaboration with Prof Mitchell Levesque, UZH

Scailyte is launching **ScaiPod**, a multi-disciplinary **partnership** framework, bringing together clinical, academic and industry partners with unique expertise. The primary goal of this precision medicine project is to generate molecular and cellular insights of **patient & biological heterogeneity** and deliver mechanistic understanding of **ICI response and resistance**. The large data lake and our expertise in developing clinically-relevant discoveries will fuel the development of new companion diagnostics and personalized treatments for cancer patients.



Scailyte Inc.

Basel

www.scailyte.com

contact@scailyte.com